Foundation, Ariad Partner on Genomic Profiles of Lung Cancer Patients | GenomeWeb

NEW YORK (GenomeWeb News) – Foundation Medicine and Ariad Pharmaceuticals today announced a deal aimed at the genomic profiling of patients enrolled in clinical trials for Ariad's investigational dual-inhibitor of ALK and EGFR for non-small cell lung cancer and other cancers.

The firms will collaborate on the generation of genomic profile information for patients enrolled in Ariad's ongoing Phase 1/2 trial for its drug AP26113, and data will be matched with clinical observations to better understand the activity and selectivity of the drug, Foundation and Ariad said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.